Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Cancer cells evade apoptosis through p53 mutations or Bcl-2 family protein overexpression, leading to malignant transformation and therapeutic resistance.
• Checkpoint kinase 1 (Chk1) plays a critical role in the DNA damage response, and its inhibition is being explored as a cancer therapy strategy.

Purpose of the Study:

• To investigate the mechanism by which Chk1 inhibition restores DNA damage-induced apoptosis in cancer cells.
• To identify the key molecular players and pathways involved in Chk1-inhibitor-mediated cell death.

Main Methods:

• Utilized zebrafish embryos with p53 mutations and human tumor cell lines.
• Employed gamma-radiation to induce DNA damage.
• Assessed apoptosis, DNA fragmentation, and the activation of caspases (caspase-3, caspase-2) and kinases (ATM, ATR).
• Investigated the role of p53 and Bcl-2 family proteins in the apoptotic process.

Main Results:

• Depletion or inhibition of Chk1 restored gamma-radiation-induced apoptosis in p53 mutant zebrafish embryos.
• A novel apoptotic program, independent of caspase-3 activation, was identified.
• This alternative pathway requires ATM, ATR, and caspase-2, and is unaffected by p53 loss or Bcl-2/xl overexpression.
• Chk1 inhibitor-treated human tumor cells activated ATM, ATR, and caspase-2, leading to caspase-2-dependent apoptosis that bypassed p53 deficiency and Bcl-2 excess.

Conclusions:

• The evolutionarily conserved "Chk1-suppressed" pathway represents a novel apoptotic process.
• This pathway is responsive to Chk1 inhibitors and is insensitive to alterations in p53 and Bcl-2.
• Targeting Chk1 offers a promising therapeutic strategy for cancers with defects in apoptosis regulation, irrespective of p53 or Bcl-2 status.